## Supplementary Tables and Figures

**Table S1.** Patient attrition

**Table S2**. Baseline clinical characteristics

†Patients’ data are weighted by the inverse of their covariate balanced propensity score; post-weighting sample sizes are sums of patients' inverse probability of treatment weights and are therefore not whole numbers for the lanadelumab cohort.

‡*CPT* code defined as surgery by the HCUP using a broad definition, or an *ICD-10* procedure code defined by HCUP as a major or minor diagnostic or therapeutic procedure.  
§*CPT* code defined as surgery by HCUP using a narrow definition, or an *ICD-10* procedure code defined by HCUP as a major diagnostic or therapeutic procedure.

ACE: angiotensin-converting enzyme; *CPT*: *Current Procedural Terminology*; DCI: Deyo Charlson Comorbidity Index; HAE: hereditary angioedema; HCUP = healthcare cost and utilization project; *ICD-10*: *International Classification of Diseases, Tenth Revision*; SD: standard deviation; STD: standardized difference.

**Table S3.** Baseline all-cause healthcare utilization

†Patients' data are weighted by the inverse of their covariate balanced propensity score; post-weighting sample sizes are sums of patients' inverse probability of treatment weights and are therefore not whole numbers for the lanadelumab cohort.

ER: emergency room; SD: standard deviation; STD: standardized difference.

**Figure S1**. Study design

HCRU: healthcare resource use.

**Figure S2.** Total healthcare costs during follow-up (weighted)

\*p<0.05 versus berotralstat months 0–6 for lanadelumab and other LTP.

\*\*p<0.001 versus berotralstat months 0–6 for lanadelumab but not other LTP.

HAE: hereditary angioedema; LTP: long-term prophylaxis; ODT: on-demand treatment STP: short-term prophylaxis.